Latest News and Press Releases

Pasithea Therapeutics (Nasdaq: KTTA) closes $5M public offering, adds $1.3M via warrant exercises, funding R&D for PAS-004 and other biotech innovations.

Pasithea’s PAS-004 cancer trial clears safety review; no DLTs or rash seen, advancing to 30mg dose in Phase 1 for MAPK-driven tumors.

Pasithea completes chronic toxicity studies for PAS-004, showing safety and potential for long-term use in NF1 and cancer treatment; Phase 1 trial ongoing

Pasithea Tx appoints Dr. Rebecca Brown, an expert in Neurofibromatosis and Director at Mount Sinai, to its Scientific Advisory Board to aid in PAS-004.

Pasithea Therapeutics completes enrollment and initial dosing of Cohort 2 in its Phase 1 trial of PAS-004, with interim safety data expected in Q3 2024.

Pasithea to present preclinical data at ASCO 2024 showing PAS-004 superior inhibition of NRAS cancer cells and xenograft tumors compared to current MEKi's

Pasithea Therapeutics' PAS-004 abstract accepted for ASCO poster presentation: novel MEK inhibitor shows promise for NF1 and cancer therapy.

Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.

Pasithea Therapeutics (Nasdaq: KTTA) announced positive preclinical efficacy in models conducted ahead of its planned Phase I, in-human trials in 1Q24.

Pasithea Therapeutics Discusses Outcome of Pre-IND Meeting with FDA for Clinical Development of its MEK inhibitor, PAS-004